| 820 |
Welcome Back |
Junior Oral Presentations
|
|
| 830 |
α-Synuclein Is Required for Multi-Lineage Differentiation and Structural Integrity of Olfactory Epithelium Organoids |
| 840 |
Cortical neuromodulation using a brain-machine interface to treat freezing of gait in Parkinson’s disease |
| 850 | Latent Classes of Cognitive Decline in Parkinson Disease: MRI and Serum Biomarker Correlates Maurice Paternak |
| 900 | Cost-Effectiveness of Integrated Multidisciplinary Neuropalliative Care for Advanced Parkinsonian Syndromes Karla Cantu Flores |
| 910 |
Q&A |
Ali Rajput Lectureship
|
|
| 930 |
Ali Rajput Lectureship: A Biological Classification of Parkinson’s Disease: Status and Challenges |
| 1015 |
BREAK |
Developing Canadian clinical guidelines for movement disorders
|
|
| 1030 |
Canadian guidelines for Parkinson’s disease |
| 1050 |
Canadian guidelines for Dystonia |
| 1110 |
Canadian guidelines for Ataxia |
| 1130 |
Panel Discussion and Q&A |
| 1150 |
LUNCH & Poster Session |
Novel approaches to abnormal tone and posture
|
|
| 1230 |
Is there a role for botulinum toxin in management of paratonia? |
| 1300 |
Cryoneurolysis for pathologic muscle overactivity and presumed contracture |
| 1330 |
Q&A |
Establishing a Canadian clinical trials network
|
|
| 1345 |
Current clinical trial landscape for movement disorders in Canada |
| 1405 |
Canadian clinical trial networks: lessons from the AMMI Canada Clinical Research Network |
| 1425 |
Canadian clinical trial networks: lessons from stroke |
| 1445 |
Panel Discussion and Q&A |
| 1510 |
Evaluations & Closing Remarks |
| 1530 |
Adjourn |
2026 Canadian Movement Disorders Society Congress
December 4 - 5, 2026
